Hagop Kantarjian, MD, on Blinatumomab in Precursor B-Cell ALL

2014 ASH Annual Meeting

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 379, “BLAST: A Confirmatory, Single-Arm, Phase II Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE) Antibody Construct, in Patients With Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia,” and abstract 3704, “An Evaluation of Molecular Response in a Phase II Open-Label, Multicenter Confirmatory Study in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Receiving Treatment With the BiTE Antibody Construct Blinatumomab,” presented by Nicola Gökbuget, MD.

Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 3251, “An Open-Label, Phase II, Dose-Finding Study of Sotatercept (ACE-011) in Patients With Low or Intermediate-1–Risk Myelodysplastic Syndromes or Nonproliferative Chronic Myelomonocytic Leukemia and Anemia Requiring Transfusion,” presented by Rami S. Komrokji, MD.

Leukemia

Linda J. Burns, MD

Linda J. Burns, MD, on the BLAST Study

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 379, “BLAST: A Confirmatory, Single-Arm, Phase II Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL),” presented by Nicola Gökbuget, MD.

Time: 1:11

Hematologic Malignancies

Ayalew Tefferi, MD

Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis

Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 634, “Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study.”

Leukemia

Lymphoma

Julie M. Vose, MD, MBA, FASCO

Julie M. Vose, MD, MBA, FASCO, on Ublituximab Plus TGR-1202 in Lymphoma

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 801, “Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Next-Generation Once-Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pretreated and High-Risk Chronic Lymphocytic Leukemia and B-Cell Lymphoma,” presented by Matthew A. Lunning, DO.

Lymphoma

Laurie Sehn, MD

Laurie Sehn, MD, on Radiotherapy in Limited-Stage Diffuse Large B-Cell Lymphoma

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 393, “R-CHOP With or Without Radiotherapy in Nonbulky Limited-Stage Diffuse Large B-Cell Lymphoma: Preliminary Results of the Prospective Randomized Phase III 02-03 Trial From the Lysa/Goelams Group,” presented by Thierry Lamy, MD, PhD.

Aug

Today In Oncology

Hagop Kantarjian, MD, on Blinatumomab in Precursor B-Cell ALL

Related Videos

Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes

Linda J. Burns, MD, on the BLAST Study

Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis

Julie M. Vose, MD, MBA, FASCO, on Ublituximab Plus TGR-1202 in Lymphoma

Laurie Sehn, MD, on Radiotherapy in Limited-Stage Diffuse Large B-Cell Lymphoma

Neoadjuvant Osimertinib in the Perioperative Setting for Resectable EGFR-Mutated NSCLC

Can Autoimmune Diseases Increase the Risk of Digestive System Cancer

Are Postmastectomy Implant-Based Breast Reconstructions Associated With Lymphomas of the Breast?

John Byrd Named UPMC Hillman Cancer Center Director

OHSU Knight Cancer Institute Receives 2 Billion Commitment From Phil and Penny Knight